The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
This open study includes patients with chronic hepatitis C who received treatment with the new direct-acting antivirals between November 1, 2014 and December 31, 2017, who achieved a sustained viral response at week 12.
Study Type
OBSERVATIONAL
Enrollment
321
Hospital Universitario Virgen macarena
Seville, Spain
Number of patients with a progression of liver injury.
To assess the evolution of liver injury with fibrosis data in patients who achieved SVR after treatment with direct-acting antivirals.
Time frame: Up to 4 weeks
Identify patients who develop liver-related events (liver decompensation, hepatocellular carcinoma, and death) after achieving sustained viral response.
Development of hepatic decompensation, defined as a patient with ascites, spontaneous bacterial peritonitis (PBR), digestive bleeding of varicose origin, or hepatic encephalopathy at some point in the evolution from SVR until the end of study follow-up.
Time frame: Up to 4 weeks.
Rate of risk factors presented by patients.
Identify risk factors in patients who develop liver complications after achieving sustained viral response.
Time frame: Up to 4 weeks.
Absence of improvement in non-invasive fibrosis parameters vs the development of liver complications.
To determine if there is a relationship between the absence of improvement in non-invasive fibrosis parameters and the development of liver complications.
Time frame: Up to 4 weeks.
Clinical and fibrosis data.
To compare the clinical and fibrosis data between patients who develop liver complications and those who do not.
Time frame: Up to 4 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.